Stakeholder feedback regarding a statewide protocol for pharmacists to prescribe tobacco cessation medications

IF 1.8 Q3 PHARMACOLOGY & PHARMACY

Exploratory research in clinical and social pharmacy Pub Date : 2025-08-25 DOI:10.1016/j.rcsop.2025.100650

Lindsey Votaw , Karen Suchanek Hudmon , Tiffany R. Shin , Elizabeth Ablah

{"title":"Stakeholder feedback regarding a statewide protocol for pharmacists to prescribe tobacco cessation medications","authors":"Lindsey Votaw , Karen Suchanek Hudmon , Tiffany R. Shin , Elizabeth Ablah","doi":"10.1016/j.rcsop.2025.100650","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Smoking contributes to negative clinical and economic outcomes in the United States, yet most adults who smoke and report wanting to quit do not access counseling or use medications to assist cessation. In rural states, such as Kansas, access to evidence-based tobacco treatment is more challenging, and most quit attempts go unassisted. Although legislation introducing a statewide policy for pharmacists to prescribe all FDA-approved tobacco cessation medications has been implemented in other states, it is unknown if such legislation would be supported in Kansas.</div></div><div><h3>Objective</h3><div>The objective of this study was to characterize stakeholder perceptions of model language for a statewide policy permitting pharmacists to prescribe medications for tobacco cessation in Kansas.</div></div><div><h3>Methods</h3><div>A cross-sectional survey was administered to tobacco control stakeholders, who were asked to review the Indiana Statewide Protocol for Dispensing Tobacco Cessation Products by Pharmacists and provide feedback on each section, via a web-based survey. Associations, insurance carriers, governmental entities, and community pharmacies were approached for recruitment. Collected data were analyzed to identify sections receiving support and to summarize feedback for recommendations to modify the protocol language.</div></div><div><h3>Results</h3><div>Fifteen surveys (34 %) were completed, representing various stakeholder organizations and community pharmacies in Kansas. Sections receiving the most feedback include the introduction, purpose, pharmacist qualifications, products covered, health screening, and referral of high-risk patients.</div></div><div><h3>Conclusion</h3><div>Findings suggest that most tobacco control stakeholders in Kansas will be supportive of a statewide protocol for pharmacists to independently prescribe tobacco cessation products. Sections will be modified, based on respondents' feedback, to create a revised protocol that will be mutually acceptable to all stakeholders.</div></div>","PeriodicalId":73003,"journal":{"name":"Exploratory research in clinical and social pharmacy","volume":"20 ","pages":"Article 100650"},"PeriodicalIF":1.8000,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Exploratory research in clinical and social pharmacy","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2667276625000915","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Smoking contributes to negative clinical and economic outcomes in the United States, yet most adults who smoke and report wanting to quit do not access counseling or use medications to assist cessation. In rural states, such as Kansas, access to evidence-based tobacco treatment is more challenging, and most quit attempts go unassisted. Although legislation introducing a statewide policy for pharmacists to prescribe all FDA-approved tobacco cessation medications has been implemented in other states, it is unknown if such legislation would be supported in Kansas.

Objective

The objective of this study was to characterize stakeholder perceptions of model language for a statewide policy permitting pharmacists to prescribe medications for tobacco cessation in Kansas.

Methods

A cross-sectional survey was administered to tobacco control stakeholders, who were asked to review the Indiana Statewide Protocol for Dispensing Tobacco Cessation Products by Pharmacists and provide feedback on each section, via a web-based survey. Associations, insurance carriers, governmental entities, and community pharmacies were approached for recruitment. Collected data were analyzed to identify sections receiving support and to summarize feedback for recommendations to modify the protocol language.

Results

Fifteen surveys (34 %) were completed, representing various stakeholder organizations and community pharmacies in Kansas. Sections receiving the most feedback include the introduction, purpose, pharmacist qualifications, products covered, health screening, and referral of high-risk patients.

Conclusion

Findings suggest that most tobacco control stakeholders in Kansas will be supportive of a statewide protocol for pharmacists to independently prescribe tobacco cessation products. Sections will be modified, based on respondents' feedback, to create a revised protocol that will be mutually acceptable to all stakeholders.

查看原文本刊更多论文

利益相关者对药剂师开出戒烟药物的全州协议的反馈

在美国，吸烟会导致负面的临床和经济结果，然而大多数吸烟并报告想要戒烟的成年人没有获得咨询或使用药物来帮助戒烟。在农村地区，如堪萨斯州，获得基于证据的烟草治疗更具挑战性，大多数戒烟尝试都没有得到帮助。尽管其他州已经实施了一项立法，要求药剂师开出所有经fda批准的戒烟药物，但尚不清楚堪萨斯州是否会支持这一立法。本研究的目的是表征利益相关者对堪萨斯州允许药剂师开戒烟药物的全州政策的模式语言的看法。方法对烟草控制利益相关者进行横断面调查，要求他们审查印第安纳州药剂师分发戒烟产品的协议，并通过基于网络的调查对每个部分提供反馈。与协会、保险公司、政府机构和社区药房接洽进行招募。对收集到的数据进行分析，以确定得到支持的部分，并总结反馈意见，提出修改协议语言的建议。结果完成了15项调查（34%），代表了堪萨斯州的各种利益相关者组织和社区药房。收到最多反馈的部分包括介绍、目的、药剂师资格、涵盖的产品、健康筛查和高危患者的转诊。结论：研究结果表明，堪萨斯州的大多数烟草控制利益相关者将支持药剂师独立开戒烟产品的全州协议。将根据受访者的反馈修改部分内容，以创建所有利益相关者都能接受的修订协议。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊